Trial Profile
The clinical study on the safety and effectiveness of Apatinib Mesylate in locally advanced head and neck soft tissue sarcoma with the induction chemotherapy treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Head and neck cancer; Soft tissue sarcoma
- Focus Therapeutic Use
- 06 Dec 2017 New trial record